Loxo '292 And Cancer Drug Development Today: So Much Promise, So Many Questions

11:42 EDT 3 Jun 2018 | SCRIP

Loxo data on the RET inhibitor LOXO-292 impressed at ASCO, so much so the company is looking to talk to...

More From BioPortfolio on "Loxo '292 And Cancer Drug Development Today: So Much Promise, So Many Questions"